Prestige Consumer Healthcare/$PBH
1D1W1MYTD1Y5YMAX
Capital at risk
About Prestige Consumer Healthcare
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
- Ticker
- $PBH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 890
- Headquarters
- Tarrytown, United States
- Website
- www.prestigebrands.com
PBH Metrics
BasicAdvanced
$2.1B
12.58
$3.58
0.33
-
Price and volume
Market cap
$2.1B
Beta
0.33
52-week high
$71.07
52-week low
$42.62
Average daily volume
537K
Financial strength
Current ratio
3.23
Quick ratio
1.798
Long term debt to equity
1.066
Total debt to equity
1.077
Interest coverage (TTM)
6.36%
Profitability
EBITDA (TTM)
325.373
Gross margin (TTM)
54.77%
Net profit margin (TTM)
15.57%
Operating margin (TTM)
26.52%
Effective tax rate (TTM)
26.57%
Revenue per employee (TTM)
$1,240,000
Management effectiveness
Return on assets (TTM)
4.58%
Return on equity (TTM)
9.12%
Valuation
Price to earnings (TTM)
12.578
Price to revenue (TTM)
1.952
Price to book
1.11
Price to tangible book (TTM)
-1.08
Price to free cash flow (TTM)
9.162
Free cash flow yield (TTM)
10.91%
Free cash flow per share (TTM)
4.908
Growth
Revenue change (TTM)
-1.36%
Earnings per share change (TTM)
-16.09%
3-year revenue growth (CAGR)
-0.75%
10-year revenue growth (CAGR)
2.98%
3-year earnings per share growth (CAGR)
28.22%
10-year earnings per share growth (CAGR)
10.72%
What the Analysts think about PBH
Analyst ratings (Buy, Hold, Sell) for Prestige Consumer Healthcare stock.
Analyst projections of the future price of Prestige Consumer Healthcare stock.
Bulls say / Bears say
Prestige completed its $1.045 billion acquisition of the Breathe Right® brand (net $900 million after tax benefits) in June 2026, adding a category-leading nasal strip franchise with ~$200 million revenue and $95 million core profit that is expected to be immediately accretive to core profit. (Reuters) (Globe Newswire)
In Q1 fiscal 2027 ended June 30, 2026, Prestige delivered revenue of $265.7 million (up 6.5% YoY), organic sales growth of 3.2%, and adjusted EPS of $0.98 (versus $0.95 prior year), exceeding estimates and prompting an upgraded full-year outlook to $1.29–$1.315 billion in revenue and $4.55–$4.65 in adjusted EPS. (Globe Newswire) (Reuters via TradingView)
The company’s niche brand-building strategy continues to drive e-commerce growth, with market share gains of +2.1 percentage points in the 12 weeks ended March 22, 2026, led by strong online consumption trends. (SEC Form 8-K)
In Q4 FY26, Prestige reported EPS of $1.23, missing consensus by $0.16, and revenue of $281.6 million versus $295.2 million expected, underscoring near-term demand softness in key categories. (Reuters)
Adjusted diluted EPS for fiscal 2026 declined to $4.38 from $4.52 in the prior year, reflecting margin compression amid promotional and input cost pressures. (SEC 8-K Filing)
Debt-funded acquisitions, including Breathe Right and LaCorium, were financed with a $1.045 billion Term Loan B and increased net leverage to ~2.6x at fiscal year end, heightening interest and refinancing risk. (SEC 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
PBH Financial Performance
Revenues and expenses
PBH Earnings Performance
Company profitability
Upcoming events
No upcoming events
PBH News
AllArticlesVideos
Funds containing PBH
AllUSDGBPEUR
Fund name | Fund size | $PBH weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.13% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.07% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.